Myrbetriq

Myrbetriq (generic name: mirabegron) is a new drug that is primarily prescribed to treat the symptoms of an overactive bladder, including incontinence (loss of bladder control), a strong need to urinate right away, or a frequent need to urinate. It may also be prescribed to treat neurogenic detrusor overactivity, a bladder dysfunction frequently observed in children with conditions such as multiple sclerosis (MS) and spinal cord injury (SCI).
Mirbagron acts on receptors in the bladder (beta-3 adrenergic receptors). Activating these receptors leads to the relaxation of the bladder and the relief of the symptoms characteristic of an overactive bladder.
Studies have reported that mirabegron or other selective β3‐Adrenergic Receptor (β3AR) agonists could help treat humans by promoting adipose tissue (AT) “beiging,” which could perhaps help in the treatment of metabolic disorders like obesity and type 2 diabetes (T2D) Dosage Take Myrbetriq only as prescribed. If a dose is missed and less than twelve hours from the scheduled time for the next dose, take it as soon as possible. However, if it is more than twelve hours, skip the missed dose and return to the regular dosing schedule.
The medicine comes with a Product Insert leaflet. Take care to read and follow the instructions carefully.
The extended-release tablet should be swallowed whole and with water. Do not crush, break, or chew it. Adults can take the tablet with or without food. Children should take the tablet with food.